PARIS, Dec. 3, 2018
PARIS, Dec. 3, 2018 /PRNewswire/ --
The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.
CAR T Cell Therapy is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases. The recent approvals of the first CAR T Cell treatments in Europe provide a great opportunity to fight hematologic malignancies, but also poses serious challenges given the peculiar nature of the treatment.
Patients, physicians, nurses, hospitals and the whole health care system need to learn how to select the right patients, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T Cell Therapy.
Christian Chabannon, Chair, EBMT Cellular Therapy & Immunobiology Working Party and EBMT Scientific Council Vice-Chair, explains: "The EBMT and EHA unite in designing this first-ever European Meeting which represents an amazing educational opportunity for healthcare professionals to get practical information to safely administer CAR-T Cells to a growing number of patients, both in Europe and worldwide."
Hermann Einsele, Chair of the EHA Scientific Working Group on Immune Therapies for Hematologic Disorders adds: "Experts with various backgrounds and expertise will share their knowledge about CAR-T Cell Therapy and provide an overview of their current and future applications in cancer treatment, and how this translates in healthcare organizations."
In addition, the program will include a comprehensive outlook on the current research efforts to increase the efficacy of CAR T Cell Therapy, with inputs from basic researchers as well as debates involving representatives from industry.
The European Hematology Association (EHA) promotes excellence in patient care, research and education in hematology.
EHA envisions a cure for all blood disorders by connecting hematologists worldwide, supporting their career development, harmonizing hematology education and advocating the interests of hematology and hematologists in the European arena.
With more than 4,000 members from 100+ countries, EHA is Europe's largest professional organization supporting both clinicians and scientists around the globe in their efforts to cure blood diseases.
For more information about our organization, activities and advocacy, please visit www.ehaweb.org or follow us on Facebook (EuropeanHematologyAssociation), LinkedIn (EHA) and Twitter (@EHA_hematology).#
The European Society for Blood and Marrow Transplantation (EBMT) is a not-for-profit medical and scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patients' lives.
The EBMT Members - more than 4,000 physicians, nurses, scientists and other healthcare professionals - participate in a unique collaborative network of peers involved in haematopoietic stem cell transplantation (HSCT) and cellular therapy research.
The EBMT patient Registry was established in the early 1970's. It is the only data source of its kind in Europe. The data are submitted continuously by more than 600 centres, including from outside Europe. The Registry holds data on more than 600,000 HSCT procedures including details on disease, transplant type, donor type and stem cell source. It contains data on patients that have undergone HSCT and also on patients receiving immunosuppressive therapies or other cell therapies. The Registry also offers the possibility to enter donors' follow-up data, which is crucial to ensure maximum donor safety. The Registry underpins extensive European research that translates into changes in clinical practice and improvements in patient outcome and care.
For further information about the EBMT, please visit the website: www.ebmt.org and follow us on Twitter: @TheEBMT